Statistics for Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study
Total visits
| views | |
|---|---|
| Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study | 340 |
Total visits per month
| views | |
|---|---|
| May 2024 | 0 |
| June 2024 | 0 |
| July 2024 | 0 |
| August 2024 | 0 |
| September 2024 | 0 |
| October 2024 | 0 |
| November 2024 | 0 |
Top country views
| views | |
|---|---|
| United States | 232 |
| Germany | 54 |
| Sweden | 6 |
| Ukraine | 6 |
| China | 5 |
| United Kingdom | 5 |
| Russia | 5 |
| Canada | 3 |
| Poland | 2 |
| France | 1 |
| Malaysia | 1 |
| Romania | 1 |
Top city views
| views | |
|---|---|
| Wilmington | 58 |
| Ann Arbor | 39 |
| Fairfield | 34 |
| Kiez | 27 |
| Gunzenhausen | 21 |
| Houston | 17 |
| Cambridge | 12 |
| Jacksonville | 7 |
| White Plains | 7 |
| Kiev | 6 |
| Stockholm | 6 |
| Washington | 6 |
| Kansas City | 5 |
| Nürnberg | 5 |
| Shenzhen | 5 |
| Falls Church | 3 |
| Saint Petersburg | 3 |
| Toronto | 3 |
| Warrington | 3 |
| Chicago | 2 |
| Henryk | 2 |
| Moscow | 2 |
| San Francisco | 2 |
| Abingdon | 1 |
| Bloomsbury | 1 |
| Brooklyn | 1 |
| Chandler | 1 |
| Endingen | 1 |
| Indianapolis | 1 |
| Loretto | 1 |
| Mountain View | 1 |
| New York | 1 |
| Paris | 1 |
| Philadelphia | 1 |
| Pitesti | 1 |
| Seremban | 1 |